BioMarin Pharmaceuticalvs.Neurocrine Biosciences
BMRN vs NBIX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Neurocrine Biosciences is about 1.2× larger than BioMarin Pharmaceutical by market cap; Neurocrine Biosciences trades at the lower P/E (22.0 vs 183.0).
Side by side
| BMRN | NBIX | |
|---|---|---|
| Market cap | $13.4B | $15.5B |
| Price | $66.12 | $153.37 |
| Today | +1.6% | +0.2% |
| Return YTD | +9.5% | +7.9% |
| Return 1Y | +11.1% | +13.0% |
| P/E | 183.0 | 22.0 |
| P/S | 3.9 | 4.6 |
| P/B | 2.1 | 4.2 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
BioMarin PharmaceuticalBMRN
Rare genetic disorders define the company. It sells enzyme replacement therapies and Voxzogo for dwarfism, and has taken gene therapy into hemophilia.
Full BMRN profile →Neurocrine BiosciencesNBIX
Ingrezza for tardive dyskinesia, plus a wider neurology and endocrine portfolio.
Full NBIX profile →More BMRN & NBIX comparisons
Other head-to-heads in the Biotech & innovation segment.
See where BMRN and NBIX sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →